841 related articles for article (PubMed ID: 28166836)
1. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
2. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
3. Intracellular pH-Triggered, Targeted Drug Delivery to Cancer Cells by Multifunctional Envelope-Type Mesoporous Silica Nanocontainers.
Yang K; Luo H; Zeng M; Jiang Y; Li J; Fu X
ACS Appl Mater Interfaces; 2015 Aug; 7(31):17399-407. PubMed ID: 26196506
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
5. In situ biodegradable crosslinking of cationic oligomer coating on mesoporous silica nanoparticles for drug delivery.
Wang Y; Wang J; Yang Y; Sun Y; Yuan Y; Li Y; Liu C
Colloids Surf B Biointerfaces; 2017 May; 153():272-279. PubMed ID: 28279933
[TBL] [Abstract][Full Text] [Related]
6. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
7. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
8. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
9. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
10. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
11. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
13. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
14. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
15. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
[TBL] [Abstract][Full Text] [Related]
16. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells.
Li J; Liu F; Shao Q; Min Y; Costa M; Yeow EK; Xing B
Adv Healthc Mater; 2014 Aug; 3(8):1230-9. PubMed ID: 24550203
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
20. Multistage pH-responsive mesoporous silica nanohybrids with charge reversal and intracellular release for efficient anticancer drug delivery.
Yuan X; Peng S; Lin W; Wang J; Zhang L
J Colloid Interface Sci; 2019 Nov; 555():82-93. PubMed ID: 31377647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]